Function Health Company Overview & Business Model

What Is Function Health and How Does the Business Model Work?

Function Health is a membership-based laboratory and telehealth company. Members pay a flat annual fee, get two blood draws per year at a Quest Diagnostics location, and receive results interpreted through the Function platform by a licensed physician. The company does not operate its own labs; it contracts with Quest Diagnostics for specimen processing, which means turnaround times and geographic availability depend on Quest's network.

The business model is a subscription-plus-interpretation play. Function buys lab tests at scale, bundles them, and adds a physician-review layer on top. The margin comes from the difference between what Function pays per-panel wholesale and the $499 annual membership fee, minus platform and clinical operations costs. This is structurally similar to how One Medical (now Amazon Clinic) monetizes primary care: charge a flat fee, reduce friction, and make money on volume rather than per-visit billing.

Revenue Model Details

Function does not bill insurance. Every dollar of revenue is direct-to-consumer. This simplifies operations but also limits addressable market to people who can pay $499 out of pocket without reimbursement. Health savings accounts (HSAs) and flexible spending accounts (FSAs) can generally be used for laboratory services, though members should verify with their plan administrator.

The company raised $52 million in Series A funding in 2023, led by General Catalyst, signaling that institutional investors view the subscription-lab category as viable at scale. That capital was earmarked for engineering, clinical team expansion, and opening enrollment beyond the initial waitlist.

What the Membership Actually Includes

Two comprehensive lab panels per year sit at the core. Each panel covers categories including metabolic function, thyroid (TSH, free T3, free T4, TPO antibodies), hormones (testosterone, estradiol, DHEA-S, SHBG), lipids (standard plus ApoB and Lp(a)), inflammation (hsCRP, homocysteine), nutrients (vitamin D, B12, ferritin, magnesium), kidney and liver function, and select cancer-adjacent markers (PSA for men, CA-125 as an optional add-on). The physician review is asynchronous; a clinician reads results and adds notes within the platform, but this is not a synchronous visit.

Is Function Health Legitimate?

Function Health is a legitimate, licensed telehealth entity operating under state medical practice laws. Its physician network holds valid state licenses, Quest Diagnostics is a CLIA-certified laboratory, and the company is incorporated as a Delaware corporation with disclosed investors and named co-founders.

What "Legitimate" Does Not Guarantee

Legitimacy as a legal and operational matter does not mean every test in its panel is clinically validated for the asymptomatic population it primarily serves. The U.S. Preventive Services Task Force (USPSTF) currently recommends against routine CA-125 screening for ovarian cancer in average-risk women, citing insufficient evidence of net benefit and potential for harm from false positives (USPSTF, 2018). Function includes CA-125 as an optional add-on, which is a reasonable disclosure model, but members should understand that optional availability does not imply clinical endorsement.

The American College of Cardiology and American Heart Association 2019 guidelines do list Lp(a) measurement as reasonable for cardiovascular risk assessment in adults with a family history of premature ASCVD (Grundy et al., 2019, Circulation). ApoB is gaining guideline traction as a superior marker to LDL-C for residual cardiovascular risk. Inclusion of both ApoB and Lp(a) represents a genuine clinical advance over a standard lipid panel.

Physician Oversight Quality

The asynchronous review model is not equivalent to an in-person visit. A physician reading labs without a contemporaneous history, physical exam, or the ability to ask follow-up questions will miss contextual factors that change interpretation. Function's terms of service state that the platform does not replace a primary care physician. Members who treat Function's physician notes as a substitute for ongoing primary care are using the product outside its intended scope.

What Does Function Health Test and Prescribe?

The 100+ biomarker panel is the central product. Testing breadth is genuinely wider than a standard annual physical. A typical employer-sponsored annual physical in the United States orders a complete metabolic panel, CBC, TSH, and a lipid panel: roughly 20 discrete values. Function's panel adds ApoB, Lp(a), homocysteine, hsCRP, IGF-1, DHEA-S, free testosterone, SHBG, ferritin, magnesium, RBC magnesium, zinc, vitamin D (25-OH), B12, folate, uric acid, and several others depending on panel version.

The Prescription Question

Function's Rx capability is state-dependent and limited. The company can prescribe certain medications in states where its physicians hold licensure and where telehealth prescribing law permits it. Common prescriptions reported by members include vitamin D supplementation guidance, thyroid medication adjustments (in coordination with a member's existing prescriber), and referrals for further workup. Function does not operate as a GLP-1 prescriber in the way that platforms like Ro, Hims, or HealthRX do. It does not prescribe testosterone replacement therapy (TRT) as a standalone service. If a member's labs reveal low testosterone, Function's standard pathway is a referral recommendation, not an in-platform prescription.

Biomarker Clinical Validity: A Closer Look

Not every biomarker on a large panel carries equal evidentiary weight. IGF-1, for example, is a validated marker in the context of acromegaly and growth hormone deficiency, and low IGF-1 in adults may associate with increased all-cause mortality in observational data (Burgers et al., J Clin Endocrinol Metab, 2011). Whether knowing your IGF-1 at age 38 without symptoms changes a clinical decision is a separate question that the literature has not yet definitively answered for population-wide screening.

HsCRP and homocysteine have more established roles in cardiovascular risk stratification. The JUPITER trial (N=17,802) demonstrated that rosuvastatin reduced major cardiovascular events by 44% in patients with LDL <130 mg/dL but elevated hsCRP (>2.0 mg/L), supporting the argument that hsCRP identifies a higher-risk subgroup missed by LDL alone (Ridker et al., NEJM, 2008). This is a reasonable basis for including hsCRP in a longevity-oriented panel.

Function Health vs. Alternatives

The direct-to-consumer lab space has grown substantially since 2020. Comparing Function to its closest competitors requires separating testing breadth, interpretation quality, prescription access, and price.

Labcorp OnDemand and Quest Health

Both Labcorp OnDemand and Quest Health (formerly QuestDirect) allow consumers to order individual tests or bundled panels without a physician order in most states. Pricing is à la carte. A comprehensive wellness panel on Labcorp OnDemand covering metabolic, thyroid, lipid, and CBC markers runs approximately $150 to $300 depending on the bundle. You do not get physician interpretation included; results are delivered raw into an online portal.

For a member who wants ApoB, Lp(a), hsCRP, and a hormone panel twice a year with interpretation, Function's $499 annual price likely comes out cheaper than ordering equivalent tests à la carte. The interpretation layer and the curated result experience represent genuine added value over raw lab portals.

InsideTracker

InsideTracker (Segterra, Inc.) offers a similar concept: a large biomarker panel with algorithmic interpretation and lifestyle recommendations. Its "Ultimate" plan covers 43 biomarkers from blood plus a DNA add-on for approximately $699 for a single draw. Function tests more biomarkers at a lower annual price for two draws, though InsideTracker's algorithm-driven intervention recommendations are more detailed than Function's current platform.

Concierge Medicine and Direct Primary Care

A concierge medicine practice typically costs $150 to $300 per month ($1,800 to $3,600 per year) and includes same-day appointments, direct physician access, and comprehensive lab ordering. That is 3.6 to 7.2 times the cost of Function. For patients who can afford it, concierge medicine is a more complete clinical service. Function is better understood as a lab-intelligence layer for people who already have a primary care physician and want more data than their insurance-covered visit generates.

Everlywell and At-Home Testing

Everlywell ships at-home finger-prick or saliva kits for specific panels (thyroid, hormones, food sensitivity). The convenience is real, but finger-prick specimens have higher coefficients of variation for some analytes compared to venipuncture. Testosterone, in particular, is best measured from a morning venipuncture sample; capillary samples introduce additional variability. Function uses Quest venipuncture draws, which aligns with standard clinical laboratory methodology.

Function Health and Lab-Driven Longevity: What the Evidence Says

The broader "longevity medicine" movement argues that dense biomarker tracking in asymptomatic adults can identify disease earlier and allow preemptive intervention. This claim has biological plausibility and some epidemiological support, but it has not been tested in a randomized controlled trial for a subscription-lab product specifically.

What Screening Evidence Does Support

Early detection matters in specific contexts. Lipid screening in adults aged 35 to 75 has strong USPSTF support for men and women with elevated cardiovascular risk (USPSTF, 2021). Thyroid screening is not universally recommended for asymptomatic adults by USPSTF, though the American Association of Clinical Endocrinology takes a more permissive stance. The divergence reflects genuine uncertainty in the evidence base, not a clear answer either way.

A 2021 analysis in JAMA Internal Medicine examining the Atherosclerosis Risk in Communities (ARIC) cohort (N=11,656) found that ApoB predicted incident cardiovascular events better than LDL-C in individuals already on statin therapy, supporting ApoB as an actionable marker rather than a curiosity (Marston et al., JAMA Cardiol, 2022). If Function's ApoB result prompts a member to initiate a statin conversation with their primary care physician, that is a legitimate clinical pathway.

Where the Evidence Falls Short

Knowing a number does not automatically produce a behavior change or a clinical intervention. A 2023 Cochrane review of general health checks (N=229,000+ across 17 trials) found that comprehensive health screenings did not reduce all-cause or cardiovascular mortality compared to usual care (Krogsboll et al., Cochrane Database Syst Rev, 2019, updated analysis). The authors noted that detecting more abnormalities does not translate to better outcomes if the downstream care system is not set up to act on findings efficiently.

This is a real limitation of Function's model. A member who discovers elevated Lp(a) (defined as >50 mg/dL by most cardiovascular guidelines, though optimal cutoffs remain debated) needs a physician willing to discuss lipoprotein apheresis eligibility, PCSK9 inhibitor use, or niacin-based protocols. Function's asynchronous review may flag the finding but cannot manage the decision tree in real time.

The Role of Serial Testing

One argument for Function's twice-yearly cadence is trend tracking rather than single-point diagnosis. A fasting glucose of 99 mg/dL is technically normal; a fasting glucose that has moved from 82 to 91 to 99 mg/dL over 18 months tells a different story. The American Diabetes Association recommends screening for prediabetes in adults aged 35 to 70 who are overweight or obese, and serial HbA1c or fasting glucose data supports early identification of deteriorating glycemic control (ADA Standards of Care, 2024). Function's twice-yearly draw cadence, if maintained consistently over years, generates that trend data in a structured format.

Function Health Pricing: Is $499 Per Year Worth It?

The value calculus depends on what you are comparing against.

The Insurance-Covered Alternative

If your primary care physician orders a comprehensive metabolic panel, CBC, TSH, and lipid panel annually under insurance, your out-of-pocket cost may be $0 to $50 depending on your plan. Function's panel adds perhaps 80 to 90 additional data points, ApoB, Lp(a), a full hormone profile, and several micronutrients that most insurance-covered physicals omit. Whether those additional data points are worth $450 to $499 annually is a personal risk-tolerance and health-curiosity decision, not a purely evidence-based one.

Who Gets Clear Value

Members with a personal or family history of cardiovascular disease, those with unexplained fatigue or metabolic symptoms, people on testosterone replacement therapy or thyroid medication who want more granular monitoring, and health-engaged individuals who want to see ApoB and Lp(a) alongside conventional lipids are the clearest beneficiaries. A 45-year-old man with a father who had a myocardial infarction at 52, who has never had Lp(a) measured, gets concrete value from a single Function draw that his annual physical never provided.

Who Gets Less Value

Healthy 28-year-olds with no symptoms, no family history, and no specific clinical questions get a data dump that their primary care physician may not know how to interpret in context, and that may generate anxiety around borderline-normal values. The psychological burden of dense lab data in low-risk individuals is real and underappreciated.

Function Health Reviews: What Members Report

Member-reported experience, aggregated from Reddit (r/longevity, r/functionhealth), Trustpilot, and health forums, follows a consistent pattern.

Positive feedback centers on three things: the surprise of discovering previously unmeasured values (commonly ApoB, Lp(a), and low vitamin D), the visual presentation of the results dashboard, and the sense of proactive health engagement. A representative member comment pattern: discovering Lp(a) of 180 nmol/L with no prior physician ever ordering the test, leading to a cardiology referral and initiation of PCSK9 inhibitor therapy.

Negative feedback clusters around the asynchronous physician review (members who want real-time answers feel underserved), geographic limitations on Rx (members in states not covered for prescribing feel the clinical loop is incomplete), and the inability to order add-on tests between the two annual draws without additional cost.

The waitlist model has historically frustrated prospective members. Function has used scarcity as a marketing tool, which is a legitimate business tactic but creates user experience friction.

Clinical Takeaway for HealthRX Patients

If you are a HealthRX patient on TRT, GLP-1 therapy, HRT, or peptide protocols, you are already receiving more targeted lab monitoring than a Function membership alone provides. ApoB, hsCRP, HbA1c, a full hormone panel, and metabolic markers are standard monitoring elements in any well-managed hormone or metabolic therapy program. Function Health may add value as a supplemental data layer if you want twice-yearly comprehensive panels documented in a single dashboard separate from your prescriber's records, but it should not replace the lab monitoring your HealthRX clinician orders as part of your treatment protocol.

Patients with undiagnosed cardiovascular risk markers, specifically those who have never had Lp(a) or ApoB measured, represent the group most likely to receive actionable new information from a Function membership. The ACC/AHA 2019 cholesterol guidelines state that "in patients in whom a risk decision is uncertain, measurement of Lp(a) may be used to inform the treatment decision" (Grundy et al., Circulation, 2019). If a $499 annual Function subscription leads to Lp(a) measurement and a subsequent statin or PCSK9 inhibitor initiation in a patient who would otherwise have gone unidentified, the downstream cost-effectiveness is favorable. PCSK9 inhibitors reduce LDL-C by 50 to 60% and reduce major adverse cardiovascular events by approximately 15% in high-risk patients per the FOURIER trial (N=27,564) (Sabatine et al., NEJM, 2017).

Order your ApoB and Lp(a) at your next lab draw whether you use Function or not. Those two numbers, combined with hsCRP and a standard lipid panel, give your clinician more cardiovascular signal than any other combination of the same cost and complexity.